Roslyn E. Wallace - Concepedia

Author

Roslyn E. Wallace

United States Food and Drug Administration

Also Known As

John A. Violet, R E Wallace, ROSLYN WALLACE, Roslyn E. Wallace, Roslyn Wallace

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

United States Food and Drug Administration Sir Charles Gairdner Hospital Peter MacCallum Cancer Centre National Health and Medical Research Council Eastern Health

About

Roslyn E. Wallace is an author at United States Food and Drug Administration specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	1.1K
2	Cell Biology	6	6	196
3	Immunology	6	6	268
4	Pharmacology	5	5	504
5	Pathology	3	3	46

Roslyn E. Wallace

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones K. C. Murdock, Ralph G. Child, P. F. FABIO, Journal of Medicinal Chemistry Medicinal ChemistryAntitumor AgentsMedicineAnti-cancer AgentColon Tumor 26	1979	283
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial James P Buteau, Andrew Martin, Louise Emmett, The Lancet Oncology Biomarker (Medicine)Prognostic BiomarkersUrologyOncologyBiomarker Analysis	2022	239
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet Oncology UrologyOverall SurvivalGenitourinary CancerMedicineCancer Management	2023	172
Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Roslyn E. Wallace, K. C. Murdock, Robert B. Angier, PubMed Chemoprevention StrategyImmunologyMetronomic ChemotherapyPharmaceutical ChemistryTumor Biology	1979	149
Development and characerization of cell lines from subhuman primates Roslyn E. Wallace, P. J. Vasington, John C. Petricciani, In Vitro Cellular & Developmental Biology - Plant Developmental BiologyCell LinesMorphogenesisEmbryonic DevelopmentMedicine	1973	57
Limited Growth Period of Human Lung Cell Lines Transformed by Simian Virus 40 Arden W. Moyer, Roslyn E. Wallace, Herald R. Cox JNCI Journal of the National Cancer Institute Limited Growth PeriodVirus StructureViral ReplicationSynthetic VirologyPathogenesis	1964	38
Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production Roslyn E. Wallace, P. J. Vasington, John C. Petricciani, In Vitro Cellular & Developmental Biology - Plant VaccinationMucosal VaccinationVaccine DevelopmentVaccine ResearchImmunology	1973	38
Heterotransplantation of Cultured Cell Lines in Newborn Hamsters treated with Antilymphocyte Serum Roslyn E. Wallace, P. J. Vasington, John C. Petricciani Nature OocyteXenotransplantationImmunologyVeterinary ScienceHematology	1971	37
Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice. Ronald V. Citarella, Roslyn E. Wallace, K. C. Murdock, PubMed Chemoprevention StrategyCl 216942Pharmaceutical ChemistryTumor BiologyExperimental Tumors	1982	34
Development of Resistance and Characteristics of a Human Colon Carcinoma Subline Resistant to Mitoxantrone in vitro Roslyn E. Wallace, Dolores Lindh, Frederick E. Durr Cancer Investigation OncologyOncogenic AgentMedicineColorectal CancerPathology	1987	20

Page 1